Transforming Growth Factor-beta 1 Knockout Mice. A Mutation in One Cytokine Gene Causes a Dramatic Inflammatory Disease

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 1993 Jul 1

PMID 8317552

Citations 79

Authors

A B Kulkarni

S Karlsson

Affiliations

Soon will be listed here.

Citing Articles

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.

Shimizu T, Powderly J, Abdul Razak A, LoRusso P, Miller K, Kao S Front Oncol. 2024; 14:1376551.

PMID: 39534099 PMC: 11555770. DOI: 10.3389/fonc.2024.1376551.

Endocardial HDAC3 is required for myocardial trabeculation.

Jang J, Bentsen M, Kim Y, Kim E, Garg V, Cai C Nat Commun. 2024; 15(1):4166.

PMID: 38755146 PMC: 11099086. DOI: 10.1038/s41467-024-48362-6.

Hitting the Target! Challenges and Opportunities for TGF-β Inhibition for the Treatment of Cardiac fibrosis.

Vistnes M Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543053 PMC: 10975989. DOI: 10.3390/ph17030267.

Smad4-deficient T cells promote colitis-associated colon cancer an IFN-γ-dependent suppression of 15-hydroxyprostaglandin dehydrogenase.

Choi S, Huang A, Letterio J, Kim B Front Immunol. 2022; 13:932412.

PMID: 36045676 PMC: 9420841. DOI: 10.3389/fimmu.2022.932412.

TGF-β1 mediates pathologic changes of secondary lymphedema by promoting fibrosis and inflammation.

Baik J, Park H, Kataru R, Savetsky I, Ly C, Shin J Clin Transl Med. 2022; 12(6):e758.

PMID: 35652284 PMC: 9160979. DOI: 10.1002/ctm2.758.

References

Tybulewicz V, Tremblay M, LaMarca M, Willemsen R, Stubblefield B, Winfield S . Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene. Nature. 1992; 357(6377):407-10. DOI: 10.1038/357407a0. View

Koller B, SMITHIES O . Altering genes in animals by gene targeting. Annu Rev Immunol. 1992; 10:705-30. DOI: 10.1146/annurev.iy.10.040192.003421. View

Jacks T, Fazeli A, Schmitt E, Bronson R, Goodell M, Weinberg R . Effects of an Rb mutation in the mouse. Nature. 1992; 359(6393):295-300. DOI: 10.1038/359295a0. View

Johnson R, Spiegelman B, Papaioannou V . Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell. 1992; 71(4):577-86. DOI: 10.1016/0092-8674(92)90592-z. View

Shull M, Ormsby I, Kier A, Pawlowski S, Diebold R, Yin M . Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 1992; 359(6397):693-9. PMC: 3889166. DOI: 10.1038/359693a0. View

Sporn M, Roberts A . Transforming growth factor-beta: recent progress and new challenges. J Cell Biol. 1992; 119(5):1017-21. PMC: 2289722. DOI: 10.1083/jcb.119.5.1017. View

Wang Z, Ovitt C, Grigoriadis A, Ruther U, Wagner E . Bone and haematopoietic defects in mice lacking c-fos. Nature. 1992; 360(6406):741-5. DOI: 10.1038/360741a0. View

Antin J, Ferrara J . Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992; 80(12):2964-8. View

Van Kaer L, Ashton-Rickardt P, Ploegh H, Tonegawa S . TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+ T cells. Cell. 1992; 71(7):1205-14. DOI: 10.1016/s0092-8674(05)80068-6. View

10.

Kulkarni A, Huh C, Becker D, Geiser A, Lyght M, Flanders K . Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A. 1993; 90(2):770-4. PMC: 45747. DOI: 10.1073/pnas.90.2.770. View

11.

Jung S, Rajewsky K, Radbruch A . Shutdown of class switch recombination by deletion of a switch region control element. Science. 1993; 259(5097):984-7. DOI: 10.1126/science.8438159. View

12.

Roberts A, Sporn M . Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors. 1993; 8(1):1-9. DOI: 10.3109/08977199309029129. View

13.

Evans M, Kaufman M . Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981; 292(5819):154-6. DOI: 10.1038/292154a0. View

14.

Hooper M, Hardy K, Handyside A, Hunter S, Monk M . HPRT-deficient (Lesch-Nyhan) mouse embryos derived from germline colonization by cultured cells. Nature. 1987; 326(6110):292-5. DOI: 10.1038/326292a0. View

15.

Kuehn M, Bradley A, Robertson E, Evans M . A potential animal model for Lesch-Nyhan syndrome through introduction of HPRT mutations into mice. Nature. 1987; 326(6110):295-8. DOI: 10.1038/326295a0. View

16.

Capecchi M . Altering the genome by homologous recombination. Science. 1989; 244(4910):1288-92. DOI: 10.1126/science.2660260. View

17.

Capecchi M . The new mouse genetics: altering the genome by gene targeting. Trends Genet. 1989; 5(3):70-6. DOI: 10.1016/0168-9525(89)90029-2. View

18.

Zijlstra M, Bix M, Simister N, LORING J, Raulet D, Jaenisch R . Beta 2-microglobulin deficient mice lack CD4-8+ cytolytic T cells. Nature. 1990; 344(6268):742-6. DOI: 10.1038/344742a0. View

19.

Koller B, Marrack P, Kappler J, SMITHIES O . Normal development of mice deficient in beta 2M, MHC class I proteins, and CD8+ T cells. Science. 1990; 248(4960):1227-30. DOI: 10.1126/science.2112266. View

20.

Moses H, Yang E, Pietenpol J . TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell. 1990; 63(2):245-7. DOI: 10.1016/0092-8674(90)90155-8. View